- AbbVie's impressive third-quarter earnings beat expectations, showcasing resilience beyond Humira's patent expiration.
- Analyst forecasts predict a potential upside of 18.47%, with a price target range from $173.00 to $251.00.
- Despite strong performance, the GuruFocus GF Value suggests a potential downside of 6.95% from the current stock price.
AbbVie (ABBV, Financial) showcased its robust financial health in the recent third-quarter earnings report. The pharmaceutical giant reported non-GAAP earnings per share of $2.46, surpassing forecasts by $0.06. Additionally, AbbVie posted a revenue of $13.34 billion, exceeding expectations by $420 million. These results underline the company's ability to maintain growth potential beyond the widely discussed Humira patent cliff.
Wall Street Analysts' Perspective
Analysts have set their one-year price targets for AbbVie Inc (ABBV, Financial), with the average target at $213.68. This suggests a potential upside of 18.47% from the current stock price of $180.37. The high estimate is $251.00, while the low stands at $173.00. For more comprehensive details, visit the AbbVie Inc (ABBV) Forecast page.
AbbVie Inc currently enjoys a consensus recommendation rating of 2.0 from 27 brokerage firms, classifying it under the "Outperform" category. This rating scale ranges from 1, implying a Strong Buy, to 5, which indicates a Sell.
Evaluating AbbVie's GF Value
The GF Value for AbbVie Inc (ABBV, Financial) is pegged at $167.84 for the coming year. This calculation suggests a potential downside of 6.95% from the current market price of $180.37. The GF Value is GuruFocus’ proprietary metric, estimating the fair value of a stock based on its historical trading multiples, past business growth, and projected future performance. For further insights, please refer to the AbbVie Inc (ABBV) Summary page.
